Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of 131I on the in vivo management of differentiated thyroid cancer

We demonstrated that NF-κB inhibition can be a good interventional avenue to enhance therapeutic potentiation of 131I on the in vivo management of DTC.